NEXUS AG
NXU
ISIN DE0005220909 / Valor 1099292
NEXUS AG
UMushroom community rating:
About company
NEXUS AG is a European company specializing in the development of innovative software solutions for the healthcare sector. Their product offerings include a clinical information system (NEXUS / KIS) and integrated diagnostic modules (NEXUS / DIS), designed to meet the wide-ranging functional requirements of hospitals, psychiatric institutions, rehabilitation, and diagnostic centers. The company focuses on creating user-friendly process support tools that enhance efficiency and safety in patient care. With over 250,000 daily users, including doctors, nurses, and administrative staff across various healthcare facilities, NEXUS AG emphasizes close customer relationships and localized support. Employing approximately 1,700 staff members, the company operates in seven European countries and serves clients in an additional 23 countries through certified dealers. NEXUS AG's growth is evidenced by its expanding customer base and consistently increasing revenues and profits.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (16.10.2025):
NEXUS AG has delivered robust financial results for the 3rd Quarter of 2024, demonstrating substantial growth across key financial metrics compared to the same period in 2023. The company has strengthened its market position through increased sales, enhanced profitability, and strategic acquisitions, underpinning a positive outlook for the remainder of the year.
Sales Growth
Sales increased by 11.4% year-over-year, reaching KEUR 190,805 in Q3 2024 compared to KEUR 171,266 in Q3 2023. Domestic sales grew by 18.7%, while international sales saw a 3.2% rise.
Segment Revenues
The NEXUS/DE segment reported a 12.6% increase to KEUR 63,723, NEXUS/DIS surged by 29.1% to KEUR 51,482, and NEXUS/ROE grew by 4.3% to KEUR 86,677.
Profitability Enhancement
EBITDA rose by 15.2% to KEUR 40,856, EBITA increased by 19.4% to KEUR 31,743, and EBIT grew by 21.6% to KEUR 27,179, reflecting improved operational efficiency.
Net Income and Earnings Per Share
Consolidated net income surged by 16.0% to KEUR 20,267. Earnings per share increased by 15.7%, reaching EUR 1.18 compared to EUR 1.02 in the same quarter last year.
Equity and Share Performance
Equity capital grew by 4.1% to KEUR 269,205. The share price closed at EUR 55.50 on Xetra, marking a 7.4% increase from the previous year.
Employee Growth
The company expanded its workforce by 13.0%, with the quarterly average number of employees rising to 1,853 in Q3 2024 from 1,640 in Q3 2023.
Liquidity and Financial Stability
Liquidity position improved to approximately MEUR 103 as of September 30, 2024, supported by strong sales figures and effective cash flow management despite industry challenges.
Strategic Acquisitions and Developments
NEXUS AG continued to enhance its product portfolio and market presence through strategic acquisitions, including the recent acquisition of HD Clinical and the "Laboratory Information System" business unit from NEXUS INFORMATION SYSTEMS S.A., fostering significant product and cost synergies.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1424 M
Market cap (USD)
53
Daily traded volume (Shares)
69.6 / 68.7
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
